Po35
The purpose of this work is to develop a voxel-wise dose prediction system using convolutional neural network (CNN) for cervical cancer high-dose-rate (HDR) intracavitary brachytherapy treatment planning with tandem-and-ovoid (T&O) or tandem-and-ring (T&R) applicators. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Suman Gautam, Alexander F. I Osman, Dylan Richerson, Binod Manandhar, Sharmin Alam, William Y. Song Source Type: research

Po36
We report a patient receiving hemostatic high dose rate brachytherapy using intrauterine tandem insertion only. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Memory Fadziso Bvochora-Nsingo, Rohini Bhatia, Elliphine Gwangwava, Masud Rana Khan, Thabiso Itshabeng, Surbhi Grover Source Type: research

Po37
Treating multiple fractions of cervical HDR BT with a single implant can reduce the overall package time of the procedure and reduces patient anesthesia and radiation oncology personnel resources due to reduced numbers of plans generated. Intracavitary (IC) and Intracavitary/Interstitial (IC/IS) applicators can shift between brachytherapy fractions, and bladder and bowel filling can cause interfraction variations of OAR dosimetry. Interfraction dosimetry variations of single implants have not been well-quantified and it is unclear whether an adaptive replan is required for each fraction. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Michael Salerno, Rachel Trevillian, Shibu Anamalayil, Megan Kassick, Seung Won Seol, Neil Taunk, Emily Hubley Source Type: research

Po38
Adjuvant vaginal cuff brachytherapy (VCB) for endometrial cancer (EC) is typically delivered with single-channel vaginal cylinders with diameters ranging from 2.0 to 4.0 cm. Due to the unfavorable dosimetry of 2.0 cm diameter cylinders, larger diameter cylinders are used whenever possible. There are, however, occasional patients with narrow vaginal anatomy for whom only a 2.0 cm cylinder can be accommodated. In this unique population, in addition to the dosimetric challenges for a typical prescription to 5 mm depth (ie., heterogeneity of about 170% and 210% of prescription dose at the surface of the cylinder lateral walls ...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Bethel Adefres, Christopher Jason Tien, Shari Damast Source Type: research

Po39
Endometrial cancer is the 4th most common cancer in females in India as per 2020 report from National Cancer Registry Programme (NCRP). Incidence of endometrial cancer in India is 105.5 per 100,000 women with highest being observed in Bangalore and Delhi. Management of endometrial cancer remains a challenge due to an older age population with considerable comorbidity. Surgery with or without adjuvant therapy is the standard of care in endometrial cancer, whereas upfront combination of external beam radiotherapy (EBRT) and HDR (High Dose Rate) brachytherapy (BT) or BT alone is indicated for inoperable or unresectable cases....
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Asmita Kulshrestha, Krishna Ratanchandani, Sonal Patel Shah Source Type: research

Po40
Tumor coverage with conventional MRI compatible combined intracavitary/interstitial (IC/IS) applicators is scarce in some patients with locally advanced gynecological malignancies. In these cases, it is recommended to add a larger interstitial component using transperineal templates (P-ISBT). Our department has been performing this type of implant since 2005 using MUPIT applicator and CT-based planning. In 2013 we switched to MRI-based planning and a compatible applicator had to be developed. It combines an IC component (intrauterine tandem) with a perineal template and Titanium needles. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Diana Lucia Guevara-Barrera, Silvia Rodriguez Villalba, Luis Suso-Mart í, Enrique Sanchis-Sánchez, Francisco Blazquez Molina, Maria José Pérez-Calatayud, José Pérez-Calatayud, Manuel Santos Ortega Source Type: research

Po41
Cervical cancer is the second most common cancer among Indian women. Radical chemo-radiotherapy is the standard of care for the majority of patients in India since most patients get diagnosed late and have locally advanced disease. Traditional Manchester system based brachytherapy planning and dose delivery continues to be widely practiced. Cervical cancer with disease extension beyond upper vagina presents a unique problem for brachytherapy dose delivery. Ovoid in tandem in the vagina is considered ‘Non-standard application’ in the traditional Manchester system where a lower dose to ‘Point A’ is accepted respectin...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Palanikumar Gunasekar, Susan Mathews, Francis V. James, Aswin Kumar, John Joseph, Sharika V. Menon, K.M. Jagathnath Krishna Source Type: research

Po42
Disparities in race and socioeconomic factors affect patient access to cancer screening, treatment, and clinical outcomes. The aim of this project was to evaluate relationship between race and socioeconomic factors including insurance status, employment status, disability status, and distance from brachytherapy center on clinical outcomes including stage at presentation, number of nodes positive, brachytherapy technique, progression-free survival (PFS), and overall survival (OS). (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Ria Mulherkar, Hong Wang, Mark Jelenik, Hayeon Kim, Christopher J. Houser, Elangovan Doraisamy, Madeleine Courtney-Brooks, Alexander Olawaiye, John Comerci, Michelle Boisen, Jessica Berger, Joseph Kelley, Paniti Sukumvanich, Sarah Taylor, Robert Edwards, Source Type: research

Po43
Vaginal cancer (VC) is relatively a rare gynaecological malignancy. High-dose-rate (HDR) brachytherapy (BT) is used alone as monotherapy or as boost therapy in combination with external beam therapy in patients with VC. There are limited series in the literature regarding the role of HDR-BT. The present study is a retrospective analysis of the patients of VC treated with HDR-BT at our centre. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Daya Nand Sharma, Pavnesh Kumar, Surendra Saini, Ram Pukar Bharat Source Type: research

Po44
Cervical cancer is the most common cancer treated with radiation in Botswana. There is a single linear accelerator and a single HDR brachytherapy unit in the country, treating a median of 200 cervical cancer cases year. About 80% of these are treated with curative intent, using concurrent chemoradiation with brachytherapy boost. Patients in Botswana often present with advanced disease and very bulky tumours. Traditionally, patients who can not have brachytherapy are sent for external beam boost. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Memory Fadziso Bvochora-Nsingo, Rohini Bhatia, Elliphine Gwangwava, Thabiso Itshabeng, Surbhi Grover Source Type: research

Po45
Endometrial cancer (EC) is the most common gynecologic malignancy and the fourth most common cancer in women [1]. Treatment is composed of a total hysterectomy, possibly followed by adjuvant chemotherapy or radiation therapy (RT) based on risk factors and staging [2]. Consistent follow up after treatment is integral to assessing for both toxicities and recurrence. Encouraging adjuvant vaginal dilator use has been shown to prevent vaginal stenosis, a common side effect of both surgery and RT [2]. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Shubhangi Shah, Xiaoyan Deng, Emma Fields, Dipankar Bandyopadhyay, Bridget Quinn Source Type: research

Po46
For patients with inoperable locally advanced vulvar cancer (LAVC), concurrent chemoradiation is the standard of care. Given proximity to nearby critical structures, many patients with LAVC are unable to undergo surgical resection, increasing the risk of local failure in these patients. Dose-escalation of external beam radiotherapy (EBRT) has been studied as a significant means by which local control (LC) outcomes might be improved, however, sparing of critical organs at risk (OARs) remains a clinical challenge. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Hayden Anthony Ansinelli, Arjit Baghwala, Chengfeng (Brandon) Li, Ramiro Pino, E. Brian Butler, Bin S. Teh, Andrew M. Farach Source Type: research

Po47
High-dose-rate (HDR) brachytherapy is a vital part of treatment in patients with locally advanced cervical cancer. Current guidelines recommend the use of image-guided adaptive brachytherapy (IGABT). Several fractionation schedules are used in external beam radiotherapy (EBRT) and brachytherapy (BT). A retrospective analysis of patients treated with radio(chemo)therapy and HDR brachytherapy due to cervical cancer was conducted. We compared the efficacy of two fractionation schedules implemented in our department. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Magdalena Anna Stankiewicz Source Type: research

Po48
Interruptions in High-dose rate (HDR) brachytherapy treatments are linked to episodes of bleeding among high-risk patients during and after treatments. The stability of blood counts of Gyn cancer patients is not always guaranteed when they start brachytherapy. Certain populations are at higher risk than the others. The majority of HDR patients have completed external radiation and chemotherapy prior starting brachytherapy treatments. Frequently, chemotherapy affects these patients ’ blood counts. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Rustica Cerillo, Amber Malloy, Mary Ann Monson, Lisa Thigpen, Kimberly DeBaun Source Type: research

Po49
To investigate practice patterns in adjuvant radiation (RT) delivery for patients with FIGO stage II endometrioid endometrial adenocarcinoma treated between 2004-2019. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Jessica Cruttenden, Christopher W. Weil, Lindsay M. Burt, Gita Suneja, David K. Gaffney, Cristina M. DeCesaris Source Type: research